Barclays PLC Increases Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Barclays PLC grew its stake in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 677.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,943 shares of the company’s stock after purchasing an additional 18,249 shares during the quarter. Barclays PLC’s holdings in Outlook Therapeutics were worth $111,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. AQR Capital Management LLC bought a new stake in Outlook Therapeutics during the 2nd quarter valued at $75,000. Christensen King & Associates Investment Services Inc. purchased a new position in shares of Outlook Therapeutics in the third quarter valued at about $55,000. Squarepoint Ops LLC bought a new position in shares of Outlook Therapeutics during the second quarter valued at about $232,000. XTX Topco Ltd purchased a new stake in shares of Outlook Therapeutics during the third quarter worth about $199,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Outlook Therapeutics in the second quarter worth about $303,000. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Stock Down 2.4 %

NASDAQ OTLK opened at $2.04 on Friday. The firm has a market capitalization of $50.82 million, a PE ratio of -0.23 and a beta of 0.53. The stock’s 50 day moving average is $2.45 and its 200 day moving average is $5.24. Outlook Therapeutics, Inc. has a twelve month low of $0.87 and a twelve month high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.06. On average, research analysts anticipate that Outlook Therapeutics, Inc. will post -2.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. BTIG Research lowered their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Guggenheim restated a “buy” rating and set a $12.00 target price on shares of Outlook Therapeutics in a report on Friday, January 17th. Chardan Capital reiterated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Outlook Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $28.07.

Outlook Therapeutics Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.